# A Study of LY3002813 in Participants With Alzheimer's Disease

> **NCT01837641** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 63 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **BIOLOGICAL:** LY3002813-IV
- **BIOLOGICAL:** LY3002813-SC
- **DRUG:** Placebo-IV

## Key facts

- **NCT ID:** NCT01837641
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05-03
- **Primary completion:** 2016-08-24
- **Final completion:** 2016-08-24
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2024-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01837641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01837641, "A Study of LY3002813 in Participants With Alzheimer's Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01837641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*